EpiPens are generally used to treat severe allergic reactions caused by food allergies as well as those caused by insect bites or stings, certain medications or latex.
Roughly 6 percent of children have a potentially life-threatening food allergy, according to data from the CDC, The Baltimore Sun reported.
The price hike for EpiPens, made by Amsterdam-based Mylan, is largely attributable to the Sanofi US’ 2015 recall of its epinephrine injector Auvi-Q because of inaccurate dosing. Sanofi’s device was the main competition to EpiPens, and a generic isn’t widely available, according to the report.
Mylan said it offers coupons to help patients afford their co-pays, as well as assistance to the uninsured and some free doses to schools. However, the high cost of EpiPens has drawn criticism from the public and lawmakers.
“It’s unconscionable that Mylan is taking advantage of a group of people who desperately need their medication to prevent life threatening allergic reactions, but I can’t say that I am surprised,” said Rep. Elijah Cummings (D-Md.), a ranking member of the House Committee on Oversight and Government Reform.
More articles on supply chain:
Letter to the editor: Amgen exec responds to ‘flawed’ cholesterol drug study
FDA approves accelerator for proton therapy system
Study finds drug company gifts influence physicians: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
